Navigation Links
Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
Date:9/21/2011

BROOMFIELD, Colo., Sept. 21, 2011 /PRNewswire/ -- Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd (LSE: BGC).

While the precise cause of migraines is not fully understood, changes in vascular tone and inflammatory processes appear to be key contributing factors.  Prostaglandins are naturally existing molecules that are integral components of both vascular and inflammatory reactions in the central and peripheral nervous systems.   There is evidence to demonstrate that prostaglandin E2 (PGE2) binding to the EP4 receptor causes dilation of small blood vessels in the brain, while leaving coronary and pulmonary arteries unaffected, and can stimulate a variety of inflammatory mechanisms.  AP-1531 is a potent and selective EP4 receptor antagonist that specifically targets PGE2-EP4 binding which may treat migraines. AP-1531 has shown promising results  in several disease models of migraine and acute pain and inflammation.  

"We are extremely pleased with the data from six Phase I studies on AP-1531 and are confident this approach will yield positive results as we initiate a Phase 2 study in migraine patients in 2012," said Steve Orndorff, President and CEO of Ariel Pharmaceuticals.  "Given that the current standard of care for moderate to severe migraines can take up to 90 minutes to provide relief and works temporarily or not at all in many patients, in addition to having potentially serious side effects, we're committed to developing a safer and more efficacious alternative that will provide better quality care to patients.  We believe AP-1531 will validate our business model of in-licensing clinic-ready drugs in acute care clinical indications to expeditiously build value for our shareholders."

Episodic migraine headaches affect more than 10% of the world population and are among the top four disabling neurological conditions.  Migraines account for an estimated 30 million days of lost productivity at a cost of up to $17 billion per year in the U.S.  Almost half of migraine patients suffer severe pain and require bed rest.  Currently, the most common migraine therapies are non-steroidal anti-inflammatory drugs (NSAIDs) and triptans (5-HTIB/1D agonists).  Shortcomings of these drugs include failure to work in a significant percentage of patients, slow speed of activity, recurrence of pain and potentially debilitating side effects, including cardiovascular and gastrointestinal toxicity.

About Ariel Pharmaceuticals, Inc.

Ariel Pharmaceuticals, Inc. is a private, specialty pharmaceutical company focused on the development and commercialization of drugs that improve quality of life for patients with acute neurological disorders and trauma.  Ariel is developing three drugs intended to meet unmet medical needs in migraine, hemorrhagic shock and post-operative cognitive decline.  The company's business strategy is based on in-licensing clinic-ready drugs in acute care clinical indications that have well-defined efficacy endpoints and where there is little to no competition in order to enable Ariel to rapidly build shareholder value.  For more information, please visit: www.arielpharma.com

Ariel Pharmaceuticals, Inc.
Steve Orndorff, PhD
President & CEO
sorndorff@arielpharma.com

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com


'/>"/>
SOURCE Ariel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ariel Ways GovBuys Awarded VA Contract
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 QGEN ... den Abschluss eines Kooperationsvertrags mit 10x Genomics ... in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology und ... Frankfurt Prime Standard: QIA) gab heute den ... die Entwicklung und Förderung umfassender Lösungen in ...
(Date:2/9/2016)... 2016   AllCare Plus Pharmacy announced today ... of Approval ® for Home Care Accreditation ... The Gold Seal of Approval ® is a ... providing safe and effective care.  ... a rigorous on-site survey in January 2016. The survey ...
(Date:2/9/2016)... 9, 2016 The leader in accelerated orthodontics, ... is the recipient of the 2015 Townie Choice ... Class II medical device that speeds up orthodontic tooth ... pain often associated with treatment, AcceleDent was selected by ... annual Orthotown survey of the most reliable ...
Breaking Medicine Technology:
(Date:2/9/2016)... Fort Worth, Texas (PRWEB) , ... February 09, ... ... restoration and reconstruction firm helping businesses recover after a disaster, announced today the ... restoration service companies in Hawaii. , “Investing in like-minded companies who ...
(Date:2/9/2016)... Charlotte, NC (PRWEB) , ... February 09, 2016 ... ... support the launch and production of its newest mobility device, the StandUp Walker. ... innovations in walker design in the last 50 years. , StandUp Walker’s novel ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today ... workloads to the cloud. Cirracore provides a secure VMware® vCloud Air based ... Internet. Transformation Solutions (TSL Partners) provides a full range of services from ...
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... ... innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ program ... each prescription referral received at our specialty pharmacy. , “Since our Pay ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul McElwee, ... after they noticed their furnace not producing any heat. Shortly after entering the home, ... heat exchanger was leaking dangerous levels of carbon monoxide into the home, at 2,000 ...
Breaking Medicine News(10 mins):